Eloisa Jantus-Lewintre, PhD, Universitat Politècnica De València, Valencia, Spain, discusses the great potential of liquid biopsy in cancer detection, monitoring, and treatment. Dr Jantus-Lewintre also discusses the use of liquid biopsy as a prognostic and predictive tool for patients receiving targeted therapy or immunotherapy, as well as for the assessment of minimal residual disease (MRD) status.
This interview took place at the International Society of Liquid Biopsy (ISLB) 2022 congress in Miami, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
